Clinical Evaluation of a Low Protein Content Formula in the First Months of Life: a RCT
Primary Purpose
Safety Issues, Infant Nutrition Disorders
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Low protein formula
Standard protein formula
Sponsored by
About this trial
This is an interventional other trial for Safety Issues focused on measuring Full term healthy infants, Low protein content formula, Safety, Growth, Body composition
Eligibility Criteria
Inclusion Criteria:
- healthy
- singleton
- full-term infants (gestational age 37/0 to 41/6 weeks)
- birth weight adequate for gestational age (>p10 and <p90 for gestational age) according to the World Health Organization growth charts.
Exclusion Criteria:
- presence of congenital diseases
- presence of chromosomal abnormalities
- presence of conditions that could interfere with growth, such as brain, metabolic, cardiac and gastrointestinal diseases, perinatal infections.
- being born to mother affected by endocrine and/or metabolic diseases
- having a family history of allergic disease
Sites / Locations
- NICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
No Intervention
Arm Label
Low protein formula group
Standard protein formula group
Breastfeeding group
Arm Description
Full term healthy infants randomized to receive a low protein formula for the first 4 months of life
Full term healthy infants randomized to receive a standard protein formula for the first 4 months of life
Breastfed full term healthy infants
Outcomes
Primary Outcome Measures
Evaluate weight
Weight (g) of each baby was measured on an electronic scale accurate to 0.1 g (PEA POD Infant Body Composition System; Cosmed, Concord, CA, US). Body length was measured to the nearest 1 mm on a Harpenden neonatometer (Holtain, Crymych, UK).
Evaluate lenght
Lenght (cm) of each baby was measured according standard procedures.
Evaluate head circumference
Head circumference was measured to the nearest 1 mm using non-stretch measuring tape.
Evaluate body composition (fat mass and fat free mass)
Body composition [fat mass and fat free mass (g)]was assessed using an air-displacement plethysmography (PEA POD Infant Body Composition System; COSMED, Italy).
Evaluate weight increase
Weight increase (g/day) was calculated as a change in body weight from weight at study enrollment divided by the time interval from enrolment to the assessment at 4 months Fat mass (g/day) and fat free mass (g/day) increases were also calculated.
Evaluate gastrointestinal tolerance
Parents were asked to keep a diary on the occurrence of gastrointestinal symptoms or any other symptoms and were contacted every two weeks either by clinic visits or phone calls.
The occurrence of spitting up, vomiting and colic, defined as intermittent attacks of abdominal pain when the baby screamed and drew up his/her legs but was well between episodes, was recorded. Colic was further classified as severe if the episodes were more than twice per day. Daily frequency of stool passage was also collected.
Evaluate occurence of adverse events
Adverse events were assessed based on inquires to the parents and on their daily records.
Secondary Outcome Measures
Evaluate body mass index (k/m2: weight/length2)
Body mass index [BMI: (Kg/m2)] was assessed for all infants enrolled at each study points.
Evaluate z-score
Z-scores values for age were then calculated using the z score calculator provided by WHO [WHO Anthro (version 3.2.2, January 2011)].
Full Information
NCT ID
NCT03035721
First Posted
January 17, 2017
Last Updated
June 28, 2017
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborators
Humana Co.Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT03035721
Brief Title
Clinical Evaluation of a Low Protein Content Formula in the First Months of Life: a RCT
Official Title
Clinical Evaluation of a Low Protein Content Formula Fed to Full Term Healthy Infants in the First Months of Life: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
June 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborators
Humana Co.Ltd.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aimed to evaluate the tolerance and safety of a low-protein formula in healthy full-term infants by investigating effects on growth and gastrointestinal tolerance and by identifying any adverse effects.
Detailed Description
Infants were randomized to receive either a standard protein formula or a low-protein formula. The composition of the low-protein formula vs the standard formula was: energy (65 vs. 68 kcal/100 mL), protein (1.2 vs. 1.7 g/100 mL).
To investigate the safety of the low-protein formula without any bias, a 4-month intervention period was selected during which the infants were fed only formula.
Anthropometric parameters (weight, length, and head circumference) and body composition were assessed at enrollment, at 2 and 4 months' of age. Parents were asked to keep a diary on the occurrence of gastrointestinal symptoms or any other symptoms and were contacted every two weeks either by clinic visits or phone calls.
The reference group was constituted by a cohort of healthy, exclusively breastfed, full-term infants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Safety Issues, Infant Nutrition Disorders
Keywords
Full term healthy infants, Low protein content formula, Safety, Growth, Body composition
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Anthropometric and body composition measurements were performed by three medical investigators who were blinded to allocated treatment.
Allocation
Randomized
Enrollment
150 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low protein formula group
Arm Type
Experimental
Arm Description
Full term healthy infants randomized to receive a low protein formula for the first 4 months of life
Arm Title
Standard protein formula group
Arm Type
Active Comparator
Arm Description
Full term healthy infants randomized to receive a standard protein formula for the first 4 months of life
Arm Title
Breastfeeding group
Arm Type
No Intervention
Arm Description
Breastfed full term healthy infants
Intervention Type
Dietary Supplement
Intervention Name(s)
Low protein formula
Intervention Description
Infants were enrolled to receive low protein formula (energy: 65 kcal/100 mL, protein: 1.2 g/100 mL, protein-to-energy ratio:1.9 g/100 kcal, carbohydrates: 8 g/100 mL, fat: 3.1 g/100 mL) for the firsts 4 months of life.
Intervention Type
Dietary Supplement
Intervention Name(s)
Standard protein formula
Intervention Description
Infants were enrolled to receive standard protein formula (energy: 68 kcal/100 mL, protein: 1.7 g/100 mL, protein-to-energy ratio:2.5 g/100 kcal, carbohydrates: 7.1 g/100 mL, fat: 3.5 g/100 mL) for the firsts 4 months of life.
Primary Outcome Measure Information:
Title
Evaluate weight
Description
Weight (g) of each baby was measured on an electronic scale accurate to 0.1 g (PEA POD Infant Body Composition System; Cosmed, Concord, CA, US). Body length was measured to the nearest 1 mm on a Harpenden neonatometer (Holtain, Crymych, UK).
Time Frame
enrollment, 2 months and 4 months
Title
Evaluate lenght
Description
Lenght (cm) of each baby was measured according standard procedures.
Time Frame
enrollment 2 months and 4 months
Title
Evaluate head circumference
Description
Head circumference was measured to the nearest 1 mm using non-stretch measuring tape.
Time Frame
enrollment 2 months and 4 months
Title
Evaluate body composition (fat mass and fat free mass)
Description
Body composition [fat mass and fat free mass (g)]was assessed using an air-displacement plethysmography (PEA POD Infant Body Composition System; COSMED, Italy).
Time Frame
enrollment, 2 months and 4 months
Title
Evaluate weight increase
Description
Weight increase (g/day) was calculated as a change in body weight from weight at study enrollment divided by the time interval from enrolment to the assessment at 4 months Fat mass (g/day) and fat free mass (g/day) increases were also calculated.
Time Frame
2 months, 4 months
Title
Evaluate gastrointestinal tolerance
Description
Parents were asked to keep a diary on the occurrence of gastrointestinal symptoms or any other symptoms and were contacted every two weeks either by clinic visits or phone calls.
The occurrence of spitting up, vomiting and colic, defined as intermittent attacks of abdominal pain when the baby screamed and drew up his/her legs but was well between episodes, was recorded. Colic was further classified as severe if the episodes were more than twice per day. Daily frequency of stool passage was also collected.
Time Frame
2 months and 4 months
Title
Evaluate occurence of adverse events
Description
Adverse events were assessed based on inquires to the parents and on their daily records.
Time Frame
2 months and 4 months
Secondary Outcome Measure Information:
Title
Evaluate body mass index (k/m2: weight/length2)
Description
Body mass index [BMI: (Kg/m2)] was assessed for all infants enrolled at each study points.
Time Frame
enrollment, 2 months and 4 months
Title
Evaluate z-score
Description
Z-scores values for age were then calculated using the z score calculator provided by WHO [WHO Anthro (version 3.2.2, January 2011)].
Time Frame
enrollment, 2 months and 4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
3 Weeks
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
healthy
singleton
full-term infants (gestational age 37/0 to 41/6 weeks)
birth weight adequate for gestational age (>p10 and <p90 for gestational age) according to the World Health Organization growth charts.
Exclusion Criteria:
presence of congenital diseases
presence of chromosomal abnormalities
presence of conditions that could interfere with growth, such as brain, metabolic, cardiac and gastrointestinal diseases, perinatal infections.
being born to mother affected by endocrine and/or metabolic diseases
having a family history of allergic disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paola Roggero, MD
Organizational Affiliation
NICU. Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy, 20122
Official's Role
Principal Investigator
Facility Information:
Facility Name
NICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan
City
Milano
ZIP/Postal Code
20122
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
29439736
Citation
Liotto N, Orsi A, Menis C, Piemontese P, Morlacchi L, Condello CC, Gianni ML, Roggero P, Mosca F. Clinical evaluation of two different protein content formulas fed to full-term healthy infants: a randomized controlled trial. BMC Pediatr. 2018 Feb 13;18(1):59. doi: 10.1186/s12887-018-1046-6. Erratum In: BMC Pediatr. 2018 Apr 12;18(1):135.
Results Reference
derived
Learn more about this trial
Clinical Evaluation of a Low Protein Content Formula in the First Months of Life: a RCT
We'll reach out to this number within 24 hrs